Levetiracetam as a first line antiseizure medication in WHO grade 2 glioma: time to seizure freedom and rates of treatment failure.

Over two-thirds of WHO grade 2 glioma patients treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first choice agent. Experiencing mainly focal seizures without progression infers a significant long-term reduction in the chance of seizure freedom. Further studies are needed to inform ASM selection.